ArticleProceedings of the National Academy of Sciences of the United States of America2024
Toward a CRISPR-based mouse model of
Erratum issuedAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.Urologic oncology · 2026Article
- Recent advances in etiology and treatment of von Hippel-Lindau Disease (VHLD).Cancer metastasis reviews · 2026Review
- Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients.Journal of translational medicine · 2025Review
- Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer.FEBS open bio · 2025Article
- Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.Scientific reports · 2025Article
- Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway.Cancer letters · 2025Article
- HIF-2α inhibitors in clear cell renal cell carcinoma: a clinical pharmacy perspective on lipid metabolism, therapeutic management, and resistance strategies.Frontiers in medicine · 2025Review
- Toward a CRISPR-based mouse model ofProceedings of the National Academy of Sciences of the United States of America · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
33 authors.
Laura A Stransky *Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Wenhua Gao *Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Laura S Schmidt *Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.ORCID 0000-0002-5050-5491
Kevin BiDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
Christopher J RickettsUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.
Vijyendra RameshDivision of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Amy JamesAnimal Research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Simone DifilippantonioAnimal Research Technical Support, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Lilia IlevaSmall Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Joseph D KalenSmall Animal Imaging Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Baktiar KarimMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.ORCID 0000-0001-9604-9762
Albert JeonMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Tamara MorganMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Andrew C WarnerMolecular Histopathology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Sevilay TuranNational Cancer Institute Center for Cancer Research, Sequencing Facility, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Joanne UniteNational Cancer Institute Center for Cancer Research, Sequencing Facility, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Bao TranNational Cancer Institute Center for Cancer Research, Sequencing Facility, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Sulbha ChoudhariAdvanced Biomedical and Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Yongmei ZhaoAdvanced Biomedical and Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21701.
Douglas E LinnQuantitative Biosciences, Merck & Co., Inc., Boston, MA 02115.
Changhong YunPharmacokinetics, Merck & Co., Inc., Boston, MA 02115.
Sripriya DhandapaniPharmacokinetics, Merck & Co., Inc., South San Francisco, CA 94080.
Vaishali ParabPharmacokinetics, Merck & Co., Inc., South San Francisco, CA 94080.
Elaine M PinheiroDiscovery Oncology Merck & Co., Inc., Boston, MA 02115.
Nicole MorrisLaboratory of Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
Lixia HeDivision of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Sean M VigeantDivision of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.
Jean-Christophe PignonHarvard Medical School, Boston, MA 02115.
Maura Sticco-IvinsHarvard Medical School, Boston, MA 02115.
Sabina SignorettiHarvard Medical School, Boston, MA 02115.
Eliezer M Van AllenDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892.ORCID 0000-0001-7983-3109
William G KaelinDivision of Molecular and Cellular Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215.ORCID 0000-0002-0574-4856
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MThe von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable MutationsR35CA210068 · NCI · DANA-FARBER CANCER INST · PI WILLIAM G. KAELIN · 2016 to 2026
$10.8MDeveloping a Translation Pipeline for VHL Mutant MalignanciesU01CA236489 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2019 to 2026
$3.8MCancer Chemical Biology and Metabolism Training ProgramT32CA236754 · NCI · DANA-FARBER CANCER INST · PI Nika N Danial, THOMAS M ROBERTS · 2019 to 2026
$2.6MHHS | NIH | National Cancer Institute (NCI) R35CA100068; P50CA101942;HHS | NIH | National Cancer Institute (NCI) T32CA236754HHS | NIH | National Cancer Institute (NCI) U01CA236489in part with Federal Funds from the National Cancer Institute, National Institutes of Health Contract No.HHSN2612015000031NCI NIH HHS HHSN261201000031CNCI NIH HHS HHSN261201500001CNCI NIH HHS HHSN261201500001GNCI NIH HHS HHSN261201500001WNCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P50 CA101942NCI NIH HHS R35 CA210068NCI NIH HHS T32 CA236754NCI NIH HHS U01 CA236489
Abstract
CRISPR is revolutionizing the ability to do somatic gene editing in mice for the purpose of creating new cancer models. Inactivation of the
Indexed as
Carcinoma, Renal CellDisease Models, AnimalKidney NeoplasmsVon Hippel-Lindau Tumor Suppressor ProteinAnimalsAxitinibCRISPR-Cas SystemsGene EditingHumansIndazolesMiceMice, Inbred C57BLAxitinibIndazolesVHL protein, mouseVon Hippel-Lindau Tumor Suppressor ProteinccRCCHIF2mouse models of ccRCCPT2399VHL
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.